Harmony Biosciences Holdings Inc (HRMY)
29.49
+0.56
(+1.94%)
USD |
NASDAQ |
Apr 26, 12:34
Harmony Biosciences Holdings Cash from Operations (TTM): 219.39M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 219.39M |
| September 30, 2023 | 169.40M |
| June 30, 2023 | 161.50M |
| March 31, 2023 | 158.17M |
| December 31, 2022 | 144.47M |
| September 30, 2022 | 155.32M |
| June 30, 2022 | 130.54M |
| March 31, 2022 | 114.88M |
| December 31, 2021 | 98.56M |
| Date | Value |
|---|---|
| September 30, 2021 | 71.07M |
| June 30, 2021 | 49.48M |
| March 31, 2021 | 36.25M |
| December 31, 2020 | -2.985M |
| September 30, 2020 | -37.02M |
| June 30, 2020 | -69.31M |
| March 31, 2020 | -91.54M |
| December 31, 2019 | -75.44M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-91.54M
Minimum
Mar 2020
219.39M
Maximum
Dec 2023
72.51M
Average
98.56M
Median
Dec 2021
Cash from Operations (TTM) Benchmarks
| Amylyx Pharmaceuticals Inc | 11.92M |
| Exelixis Inc | 333.32M |
| Insmed Inc | -536.25M |
| Arcturus Therapeutics Holdings Inc | -18.10M |
| Ultragenyx Pharmaceutical Inc | -474.81M |